Bronchial asthma, COPD
Conditions
Interventions
None listed
Sponsors
Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who satisfy the daiagnostic criteria of bronchial asthma in the Japanese Asthma guideline 2012 2) Patients who satisfy the daiagnostic criteria of COPD in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. 3) Healthy volunteer 4) Participants with SpO2>94% 5) Participants from whom written consent has been obtained 6) Patients with asthma who satisfy the presence of a clinical history regarding asthma (symptom, history of exacerbation, and physical examination) within the past year and any one of the following items:a) bronchial reversibility reflected by bronchodilator responsiveness, b) bronchial reversibility reflected by bronchodilator responsiveness 7) Patients with COPD who have FEV1/FVC ratio < 70% after bronchodilator inhalation and satisfy any one of the following items:a)Smoking history (>= 10 pack-years) or air pollution exposure, b) Presence of the hyperinflation or/and the flattening diaphragm on chest X-ray or the low attenuation area on chest CT demonstrating emphysematous change
Exclusion criteria
Exclusion criteria: 1) Patients who have exacerbations of asthma or COPD within the last 4 weeks a)Asthma exacerbation: oral corticosteroids administrated for more than 2 days because of having cough and sputum ,and/or more than 20% decrease of expiratory peak flow vales for consecutive 3 days b) COPD exacerbation: exhibition of increased shortness of breathing, increased cough and sputum that result in a change of treatment 2) Patients with allergic bronchial pulmonary aspergillosis or eosinophilic granulomatosis with polyangitis 3) Patients with following disorders: severe heart diseases, severe renal diseases, neurological diseases 4) Pregnancy or lactation 5) Patients who are considered unsuitable for enrollment in this study by physicians in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Contribution of ATP in sputum to clinical pathophysiology in asthma Measure ATP in induced sputum to determine whether concentrations of them increase in patients with asthma. | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between ATP in sputum and following clinical parameters: severity, pulmonary function, cell counts in induced sputum, exhaled oxide concentrations, cytokines, chemokines, granule proteins | — |
Countries
Japan
Contacts
Public ContactTomoyuki Soma
Saitama Medical University Department of Respiratory Medicine and Allergy Center
Outcome results
None listed